Impress employers and recruiters.
Choose from hundreds of resume examples.

Target Resume Now

About the Role

We are seeking an accomplished and entrepreneurial Vice President, Market Access to build and lead the company's U.S. Market Access organization in preparation for the anticipated launch of vidofludimus calcium for the treatment of relapsing multiple sclerosis (RMS). The ideal candidate brings deep experience in the multiple sclerosis marketplace, established relationships across national and regional payers, specialty pharmacies, and key health systems, and a proven track record of building high-performing Market Access organizations. As a member of the Commercial Leadership Team, you will help shape Immunic's overall commercialization strategy while building a best-in-class Market Access organization.

Responsibilities

Lead U.S. Market Access strategy and organization build for vidofludimus calcium's launch, covering pricing, contracting, reimbursement, and distribution.
Develop integrated access strategies spanning Commercial, Medicare, Medicaid, VA, DoD, and other government channels.
Own national payer strategy, negotiating with health plans, PBMs, IDNs, health systems, and specialty pharmacies.
Build payer value propositions using clinical, economic, and real-world evidence to drive favorable formulary coverage.
Set pricing strategy, gross-to-net assumptions, and specialty pharmacy/trade/distribution frameworks, ensuring launch-ready operations.
Partner with Medical Affairs/HEOR on payer evidence strategy, AMCP dossiers, and value communication; support post-launch evidence generation.
Serve on Commercial Leadership Team, coordinating with Marketing, Sales, Medical, Regulatory, Finance, Legal, and Supply Chain on launch readiness.
Design and build the Market Access org structure, capabilities, and metrics across Payer Strategy, Marketing, Pricing/Contracting, Trade, Analytics, and Excellence functions.
Recruit and lead a field Market Access team: National, Federal, and Regional Account Managers plus Field Reimbursement Managers.
Set field deployment strategy (territories, hiring, training, incentives) and ensure tight collaboration with Sales and Medical Affairs to maximize adoption.

Requirements

15+ years of progressive leadership experience within the pharmaceutical or biotechnology industry.
Demonstrated success leading U.S. Market Access organizations for specialty pharmaceutical products.
Direct experience leading the U.S. Market Access strategy for one or more multiple sclerosis product launches is strongly preferred.
Candidates who have played a significant leadership role in the commercialization of successful MS therapies will be strongly favored.
Deep understanding of the competitive dynamics, payer landscape, specialty pharmacy networks, treatment centers, and reimbursement environment within multiple sclerosis.
Experience negotiating with commercial payers, PBMs, Medicare Part D plans, federal healthcare systems, specialty pharmacies, and integrated health systems.
Demonstrated success building and leading field-based Market Access organizations.
Experience building commercial infrastructure within an emerging biotechnology company or first-launch organization strongly preferred.

Skills

Market Access strategy
Pricing
Contracting
Reimbursement
Distribution
Payer strategy
Value propositions
Clinical evidence
Economic evidence
Real-world evidence
Formulary coverage
Gross-to-net assumptions
Specialty pharmacy
Trade
Distribution frameworks
Evidence strategy
AMCP dossiers
Value communication
Org structure design
Field deployment strategy
Collaboration with Sales and Medical Affairs

Location

U.S.

Work Type

Full-time

Experience Level

15+ years of progressive leadership experience
Vice President

Education Level

Bachelor's degree required
MBA, PharmD, MPH, or other advanced degree preferred

About the Company

Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.
The company’s lead program, vidofludimus calcium, is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with therapeutic activity shown in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases.
The development pipeline also includes earlier-stage programs addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases.
For further information, please visit: www.imux.com.